Cellyan Biotechnology
HKPD
6 hedge funds and large institutions have $106K invested in Cellyan Biotechnology in 2026 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
198% more capital invested
Capital invested by funds: $35.5K → $106K (+$70.3K)
50% more funds holding
Funds holding: 4 → 6 (+2)
0.93% more ownership
Funds ownership: 0.57% → 1.5% (+0.93%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SG
StoneX Group
New York
|
+$34.4K |
| 2 |
Jane Street
New York
|
+$26.9K |
| 3 |
HF
HRT Financial
New York
|
+$22.9K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$21.3K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$532 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$6.16K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SG
1
StoneX Group
New York
| $52.4K | +$34.4K | +62,915 | +160% |
|
|
2
Jane Street
New York
| $18.7K | +$26.9K | +49,087 | New |
|
|
HF
3
HRT Financial
New York
| $15K | +$22.9K | +41,824 | New |
|
|
XT
4
XTX Topco
George Town,
Cayman Islands
| $14.8K | +$21.3K | +38,930 | New |
|
|
CS
5
Clear Street
New York
| $4.57K | – | – | – |
|
|
6
UBS Group
Zurich,
Switzerland
| $411 | +$532 | +971 | +883% |
|
|
7
Two Sigma Investments
New York
| – | -$6.16K | -10,832 | Closed |
|
HKPD Hedge Fund Activity: Q2 2026 in Review
6 of the 8,279 institutional investors tracked by Wall St. Rank reported a position in Cellyan Biotechnology (HKPD) for Q2 2026, worth a combined $106K — up 198% from $35.5K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new HKPD positions and 1 closed out — a net gain of 2 holders — while 2 added to existing stakes and 0 trimmed.
The largest buyer was StoneX Group, adding an estimated $34.4K. The largest seller was Two Sigma Investments, exiting entirely with an estimated $6.16K sold.
- 6 institutional investors held Cellyan Biotechnology (HKPD) as of Q2 2026, up from 4 in Q1 2026.
- Funds reported $106K of Cellyan Biotechnology stock for Q2 2026, up 198% quarter-over-quarter.
- 3 funds opened new Cellyan Biotechnology positions in Q2 2026 and 1 closed out, a net change of +2 holders.
- The largest Cellyan Biotechnology buyer in Q2 2026 was StoneX Group, an estimated $34.4K added.
- The largest Cellyan Biotechnology seller in Q2 2026 was Two Sigma Investments, an estimated $6.16K sold.
Based on aggregated 13F filings for Q2 2026.